BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2014;15:1715-1736. [PMID: 24961409 DOI: 10.1517/14656566.2014.931938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Czaja AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. Autoimmunity. 2019;52:144-160. [PMID: 31298041 DOI: 10.1080/08916934.2019.1641200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Czaja AJ. Adoptive cell transfer in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 2015;9:821-836. [PMID: 25719553 DOI: 10.1586/17474124.2015.1019470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
3 Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res 2019;2019:9437043. [PMID: 31886312 DOI: 10.1155/2019/9437043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
4 Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res 2016;46:613-21. [PMID: 26406984 DOI: 10.1111/hepr.12596] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
5 Farooq T, Rehman K, Hameed A, Akash MSH. Stem Cell Therapy and Type 1 Diabetes Mellitus: Treatment Strategies and Future Perspectives. Adv Exp Med Biol 2019;1084:95-107. [PMID: 29896720 DOI: 10.1007/5584_2018_195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
6 Luo B, Han F, Xu K, Wang J, Liu Z, Shen Z, Li J, Liu Y, Jiang M, Zhang ZY, Zhang Z. Resolvin D1 Programs Inflammation Resolution by Increasing TGF-β Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis. J Neurosci 2016;36:9590-603. [PMID: 27629711 DOI: 10.1523/JNEUROSCI.0020-16.2016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
7 Müller P, Messmer M, Bayer M, Pfeilschifter JM, Hintermann E, Christen U. Non-alcoholic fatty liver disease (NAFLD) potentiates autoimmune hepatitis in the CYP2D6 mouse model. Journal of Autoimmunity 2016;69:51-8. [DOI: 10.1016/j.jaut.2016.02.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
8 Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver. 2016;10:177-203. [PMID: 26934884 DOI: 10.5009/gnl15352] [Cited by in Crossref: 82] [Cited by in F6Publishing: 69] [Article Influence: 13.7] [Reference Citation Analysis]
9 Manns MP, Jaeckel E, Taubert R. Budesonide in Autoimmune Hepatitis: The Right Drug at the Right Time for the Right Patient. Clin Gastroenterol Hepatol 2018;16:186-9. [PMID: 29128475 DOI: 10.1016/j.cgh.2017.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
10 Christen U, Hintermann E. Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models? Int J Mol Sci 2016;17:E2007. [PMID: 27916939 DOI: 10.3390/ijms17122007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
11 Garcia-medina JJ, Pastor-grau A, del-Rio-Vellosillo M, Zanon-moreno V, Pinazo-duran MD. Unilateral and irreversible optic neuropathy associated to infliximab treatment: 3-year follow-up. Scandinavian Journal of Gastroenterology 2016;51:765-6. [DOI: 10.3109/00365521.2015.1126855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Coscia LA, Armenti DP, King RW, Sifontis NM, Constantinescu S, Moritz MJ. Update on the Teratogenicity of Maternal Mycophenolate Mofetil. J Pediatr Genet 2015;4:42-55. [PMID: 27617117 DOI: 10.1055/s-0035-1556743] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
13 Czaja AJ. Factoring the intestinal microbiome into the pathogenesis of autoimmune hepatitis. World J Gastroenterol 2016; 22(42): 9257-9278 [PMID: 27895415 DOI: 10.3748/wjg.v22.i42.9257] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
14 Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Gow P, Janko N, Tse E, Mishra G, Cheng EH, Levy M, Cheng W, Sood S, Skoien R, Mitchell J, Zekry A, George J, MacQuillan G, Wigg A, Stuart K, Sievert W, McCaughan G; ALA Clinical Research Network. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clin Gastroenterol Hepatol 2018;16:268-77. [PMID: 29050991 DOI: 10.1016/j.cgh.2017.09.063] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
15 Czaja AJ. Evolving paradigm of treatment for autoimmune hepatitis. Expert Review of Clinical Immunology 2017;13:781-98. [DOI: 10.1080/1744666x.2017.1319764] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.4] [Reference Citation Analysis]
16 Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
17 Yang Q, Wang J, Liu R, Wang Z, Li Y, Zhang Y, Hao X, Huang Y, Xie W, Wei H. Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(-)CD69(+) subset proliferation. Drug Des Devel Ther 2016;10:443-53. [PMID: 26869766 DOI: 10.2147/DDDT.S92440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
18 Castellanos Fernández MI, Cepeda Mullo ME, la Rosa Hernández D, Vega Sánchez H, González Fabian L, Gish RG, Torres González AL, Dorta Guridi Z. Autoimmune Hepatitis in Cuban Patients: A Retrospective Analysis of Clinical and Histological Profiles, Treatments, and Outcomes. Curr Ther Res Clin Exp 2020;93:100594. [PMID: 32922567 DOI: 10.1016/j.curtheres.2020.100594] [Reference Citation Analysis]
19 Steinmetz C, Kashyap A, Zhivkova N, Alizor H, Ernst I, Gottfried-Brand D, Janssen H, Teufel A, Schulze-Bergkamen H, Lotz J, Kuball J, Theobald M, Heise M, Lang H, Galle PR, Strand D, Strand S. Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. Hepatology 2017;65:2074-89. [PMID: 28108987 DOI: 10.1002/hep.29072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
20 Czaja AJ. Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis. Aliment Pharmacol Ther 2017;46:920-37. [DOI: 10.1111/apt.14324] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
21 Sheiko MA, Sundaram SS, Capocelli KE, Pan Z, McCoy AM, Mack CL. Outcomes in Pediatric Autoimmune Hepatitis and Significance of Azathioprine Metabolites. J Pediatr Gastroenterol Nutr. 2017;65:80-85. [PMID: 28272159 DOI: 10.1097/mpg.0000000000001563] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
22 Czaja AJ. Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. Dig Dis Sci. 2015;60:2881-2900. [PMID: 25999246 DOI: 10.1007/s10620-015-3708-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
23 Shahmohammadi S, Sahraian MA, Shahmohammadi A, Doosti R, Zare-Mirzaie A, Naser Moghadasi A. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Mult Scler Relat Disord 2018;22:22-6. [PMID: 29524758 DOI: 10.1016/j.msard.2018.02.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
24 T de Moraes Falcão L, Terrabuio DRB, Diniz MA, da Silva Evangelista A, Souza FG, R Cancado EL. Efficacy and safety of chloroquine plus prednisone for the treatment of autoimmune hepatitis in a randomized trial. JGH Open 2020;4:371-7. [PMID: 32514439 DOI: 10.1002/jgh3.12258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Lu FB, Hu ED, Xu LM, Hu YB, Chen L, Wu JL, Li H, Chen DZ, Chen YP. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. Exp Ther Med 2018;15:4838-50. [PMID: 29904396 DOI: 10.3892/etm.2018.6063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]